Tiziana Life Sciences Announces
Anti-CD3 mAb Research for the Treatment of Alzheimer's Disease to
be Presented by Dr. Howard Weiner at the International Conference
on Alzheimer's and Parkinson's Disease and Related Neurological
Disorders Conference in Sweden
- Data shows reduction of microglia activation and improvement in
behavior in rodent model of Alzheimer's disease (AD)
- Modulation of neuroinflammation may be synergistic to existing
treatments in AD
NEW
YORK, March 31, 2023 --
InvestorsHub NewsWire -- Tiziana Life Sciences
Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a
biotechnology company developing breakthrough immunomodulation
therapies via novel routes of drug delivery, today announced that
Dr. Howard Weiner will present positive data from a study of
intranasal anti-CD3 monoclonal antibody in an animal model of
Alzheimer's disease on April 1, 2023 at the AD/PD 2023
International Conference on Alzheimer's and Parkinson's Diseases
and Related Neurological Disorders in Gothenburg,
Sweden.
Howard L. Weiner,
M.D., Co-Director of the Ann Romney Center for Neurologic Diseases
at Brigham and Women's Hospital, a founding member of Mass General
Brigham, and Chairman of Tiziana's Scientific Advisory Board,
stated, "I believe that the modulation of innate immunity
via targeting microglia will play
a synergistic role with the currently approved anti-amyloid
Alzheimer's treatments. Our research has demonstrated that
intranasal rodent anti-CD3 mAb and intranasal fully human anti-CD3
mAb (foralumab) will decrease microglia activation in rodents and
humans, respectively."
"With the FDA
approvals of aducanumab and lecanemab, there is a renewed focus on
effective Alzheimer's disease treatments and we have the potential
to be a novel, first in class neuroinflammatory modulator ,"
commented Gabriele Cerrone, Executive Chairman and interim Chief
Executive Officer of Tiziana. "Our unique intranasal approach has
the potential that does not target beta-amyloid or other proteins,
but focuses on the neuroinflammatory process itself, which may be
complementary or synergistic with existing treatments."
"Dr. Weiner's lab
continues to be at the forefront of neuroinflammatory research and
we are fortunate to have a collaboration with Brigham and Women's
Hospital to investigate the potential applications of foralumab,"
stated Matthew W. Davis, M.D., RPh, Chief Medical Officer of
Tiziana.
About
Foralumab
Activated T cells
play an important role in the inflammatory process. Foralumab, the
only fully human anti-CD3 monoclonal antibody (mAb), binds to the T
cell receptor and dampens inflammation by modulating T cell
function, thereby suppressing effector features in multiple immune
cell subsets. This effect has been demonstrated in patients with
COVID and with multiple sclerosis, as well as in healthy normal
subjects. Intranasal foralumab Phase 2 trials are expected to start
in the third quarter of 2023 in patients with non-active
SPMS. Immunomodulation by nasal
anti-CD3 mAb represents a novel avenue for treatment of
inflammatory human diseases.[1]
About Tiziana
Life Sciences
Tiziana Life
Sciences is a clinical-stage
biopharmaceutical company developing breakthrough therapies using
transformational drug delivery technologies to enable alternative
routes of immunotherapy. Tiziana's innovative nasal, oral and
inhalation approaches in development have the potential to provide
an improvement in efficacy as well as safety and tolerability
compared to intravenous (IV) delivery. Tiziana's lead candidate,
intranasal foralumab, which is the only fully human anti-CD3 mAb,
has demonstrated a favorable safety profile and clinical response
in patients in studies to date. Tiziana's technology for
alternative routes of immunotherapy has been patented with several
applications pending and is expected to allow for broad pipeline
applications.
For further
inquiries:
Tiziana
Life Sciences Ltd
Paul Spencer,
Business Development and Investor Relations
+44 (0) 207 495
2379
email: info@tizianalifesciences.com
Investors:
Irina
Koffler
LifeSci Advisors,
LLC
646.970.4681
ikoffler@lifesciadvisors.com